Eli Lilly Australia & New Zealand

#LillyANZ acknowledges #WorldBrainDay today, a time to elevate awareness of brain health and the prevention of neurological conditions. Different factors can influence brain health. The World Health Organisation defines it as “the state of brain functioning across cognitive, sensory, social-emotional, behavioural and motor domains, allowing a person to realise their full potential over the life course, irrespective of the presence or absence of disorders.” Through ongoing clinical trials and cutting-edge research, we are committed to making scientific advancements in neuroscience that support better outcomes for people living with neurological conditions in Australia and New Zealand. Ref: World Health Organisation, 2024. Brain Health. Available at: https://lnkd.in/eSm-HZY.

Diabetes is a leading cause of other health conditions, such as blindness, dementia, stroke, mental and emotional challenges, heart and kidney disease. In the 2024 State of the Nation Report, Diabetes Australia identifies the urgent need to work collaboratively to change how diabetes is managed to improve outcomes for the almost 1.2 million Australians living with type 2 diabetes. This includes expanding access to technologies that can help those with diabetes monitor and effectively manage their condition. #LillyANZ is committed to advancing care for those living with diabetes and proudly supports #NationalDiabetesWeek2024. #UniteInTheFightForTech #diabetes #type2diabetes Ref: Diabetes Australia, 2022. Change the future: Reducing the impact of the diabetes epidemic. Unite in the fight for change report. Ref: AIHW, 2024. Diabetes: Australian facts. Available at: https://lnkd.in/gVZw4SEr.

There is still time to submit nominations for the 2024 Credentialled Diabetes Educator (CDE) of the Year Award. This is a long-standing initiative that Eli Lilly Australia is proud to support in partnership with the Australian Diabetes Educators Association (ADEA). In 2024, the awards include three new categories: Aboriginal and/or Torres Strait Islander CDE of the Year, Early Career CDE of the Year, and People's Choice CDE of the Year. Learn more and nominate an exceptional CDE here: https://lnkd.in/eWywNKHd Nominations close at midnight on Monday, 15 July 2024. #DiabetesEducator #diabetes

We are proud to announce that #LillyANZ has been selected as a finalist in the esteemed annual Australian HR Awards, for the fourth consecutive year. This year, we have been shortlisted as an Excellence Awardee in the ‘Employer of Choice (100 – 999 Employees)’ category. The 'Employer of Choice (100- 999 Employees)' category recognises the best organisations to work for in Australia in relation to excellence in leadership, engagement, communications and employee benefits. At Lilly we recognise the important role our people play in creating a rich and diverse workplace. We are committed to becoming a leading talent engine and employer of choice, where our people are equipped with the mindset and capabilities to build the future of Lilly. Read more about the Award and Lilly's submission here: https://lnkd.in/esbAdu-k #WeAreLilly #AusHRAwards

At Lilly, we value the unique identities and contributions of our LGBTQ+ community and recognise the importance of allies in creating a safe space where we can all thrive, be ourselves and feel a true sense of belonging. Throughout #PRIDEMonth and beyond, #LillyANZ strives to foster an inclusive workplace where everyone is valued, respected, and heard. This year, to celebrate PRIDE Month, the Lilly team proudly immersed themselves in several key initiatives: 🏳️🌈 PRIDE Walk: On Tuesday 25 June, the Sydney team took part in a 3km walk from our office to the Sydney Opera House, wearing our Lilly PRIDE t-shirts to embrace the spirit of the month. The walk was a chance for us to celebrate, support and be proud of the diverse, unique identities that make up our team and reflect on the history of LGBTQ+ rights in Australia and New Zealand. Our New Zealand and Australian state-based colleagues also participated, taking time out of their days for their own PRIDE Walk. 🏳️🌈 PRIDE Talk & Morning Tea: On Thursday 27 June, we were fortunate to hear from Craig Rutherford, Senior Relationship Manager, Pride in Health + Wellbeing at ACON, in an interactive session on PRIDE Month and LGBTQ+ awareness. Craig guided us through insightful conversations to understand the lived experiences of LGBTQ+ communities, learn about the diversity of gender identity and sexuality, and understand the importance of inclusion in the workplace. We explored practical steps to foster an inclusive environment, reflecting our commitment to diversity and respect. #WeAreLilly #DEI #PRIDE

Diabetes Australia has released its 2024 State of the Nation report, which reveals the diabetes epidemic shows no sign of abating. This report comes at a critical time in the national conversation about diabetes. Alarmingly, the report highlights the significant increase in young people aged 18 to 39 being diagnosed with type 2 diabetes, particularly in Aboriginal and Torres Strait Islander communities. With more than 300 people diagnosed every day and an estimated 2 million Australians now living with diabetes, enhanced prevention strategies, improved access to healthcare, and targeted investments in research are imperative to stem the tide of this epidemic. The State of the Nation includes 25 recommendations covering prevention, treatment, support for vulnerable communities and investment in research. View the full report at: https://lnkd.in/gFA-HP7s Lilly ANZ is proud to have supported the development of this important report and is committed to shifting the way diabetes is managed to improve outcomes. #diabetes #epidemic

Eli Lilly is committed to improving outcomes for Australian patients, so they can access the right treatment, at the right time. Lilly ANZ General Manager, Tori Brown, joined Rozalina Sarkezians in the latest Health Industry Hub Reimagining Healthcare Senior Leadership Series. In the podcast, Tori explores innovation readiness - the concept that by the time a medicine or technology launches, the market and patients are able to use it right away. She discusses what innovation readiness in Australia could look like over the next 10-15 years, and the important role the pharmaceutical industry has in driving efforts to achieve this. Click the link below to listen to the full podcast* and to hear Tori's thoughts on the recent Productivity Commission report, Health Technology Assessment (HTA) reform and the need for medicines to be valued for the benefits they bring, and examples of forward-looking countries that are pushing boundaries when it comes to innovation readiness. https://bit.ly/3zhqyHa * Content available to Health Industry Hub subscribers only. #WeAreLilly #StrongerPBS #thoughtleadership #innovation

Lilly was delighted to be the diamond sponsor of the Australian Dementia Research Forum (ADRF) held on the Gold Coast last week. “Bringing together leading researchers and the health care community, it was fascinating to explore how innovative research, meaningful policy change and scientific breakthroughs are being pioneered in dementia. Most importantly, it was humbling to connect with the experiences of those living with the condition and their families. On behalf of Lilly Australia, we thank the Australian Dementia Network and all who were involved in this important forum. We are excited by the science – and what the future holds for improving the management of this condition,” said Vinay Prusty, Executive Director of Medical Neuroscience at Lilly Australia, New Zealand and North Asia Pacific. For over three decades, Lilly has remained committed to scientific discovery and clinical research in Alzheimer’s disease. With all that experience behind us, we are now focused on developing breakthroughs for Australians living with the condition.

Did you know? Two in five (42%) Australians are not confident that the Pharmaceutical Benefits Scheme (PBS) would be available to them or their loved ones if they were diagnosed with a life-limiting or life-changing condition. At Lilly, we understand the importance of access to quality healthcare, which is why we are proud to support the StrongerPBS campaign. Health crises don't wait, and neither should access to the necessary treatments. A #StrongerPBS is critical to ensure that every Australian can get timely access to the treatments they deserve, without compromise. 👉 Visit www.strongerpbs.com.au to learn more. #StrongerPBS #WeAreLilly

Committed to driving scientific progress to improve outcomes for people living with Alzheimer’s disease, Lilly is delighted to attend the Australian Dementia Research Forum (ADRF) on 3-5 June. ADRF is the premier annual event for Australian dementia research. It is an opportunity for health professionals, policy makers, researchers, and people living with dementia, their families and carers, to come together to discuss the latest in the field of dementia. Lilly is sponsoring the Biomarkers session on Wednesday 5 June at 11:10am – 12:10pm. Join us to hear from leading researchers as they delve into insightful discussions on cutting-edge research aimed at identifying biomarkers that can diagnose Alzheimer’s disease early and pinpoint its risk factors. We invite those attending to visit us at Booth #11 to learn more about Lilly’s commitment to Alzheimer’s Disease. To find out more about the 2024 ADRF, visit: https://lnkd.in/eciAJgxT